StockData
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31

CORCEPT THERAPEUTICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$112.10+1.94 (+1.76%)

Close on Oct 19, 2026

Market cap
$13.27B
P/E (TTM)
266.9
Dividend yield
–

CORCEPT THERAPEUTICS INC revenue by segment

No segment breakdown reported

Corcept Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.